Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Justin J. Kennedy leads new Programme in Personal Excellence
2012-05-08

 

Justin J. Kennedy
Photo: Leatitia Pienaar
8 May 2012

Justin J. Kennedy has been appointed as the Manager of the new Programme in Personal Excellence. The programme is hosted in the Centre for Business Dynamics, the commercial unit of the Business School.

He studied at Rhodes University and the University of the Western Cape (UWC) and his research has been published in various health-related publications. His D.Psych. at the University of California migrated into a Ph.D. with research partner DiscoveryHealth.

While in New York, he was part of the research laboratory Helicor that developed the world’s first hand-held medical device for measuring heart-rate variability of the peripheral nervous system.  This device forms part of the programmes offered to control stress and improve cognitive performance as per clinical trials at the UCT Department of Human Biology. This programme evolved into developing the M.Sc. course work on occupational stress and Ph.D. student supervision.

The programme will launch during the university's Beneficiary Programme for Academic Heads of Department, and will focus on the neuro-economics of stress resilience.

Justin’s most recent research is peer review for an international leadership journal where he has presented evidence on how people can improve their cognitive performance and working memory by building functional stress resilience. The overall aim of the programme is to not only reduce stress, but to improve ability to be excellent at work.  Clinical results have shown it is beneficial for performance anxiety, insomnia, migraine, hypertension control and improved ability at cognitive tasks.  The aim of his work is to ensure that simple and practical skills provide academics, students and corporate participants with enduring, functional techniques that are easily applied in their working lives.

The programme has three roles: to offer services that equip students and academics; consulting services to corporate clients, financial groups and private hospitals; and publication of results in peer-reviewed journals. 

This initiative also envisages offering a postgraduate qualification and selected coaching qualifications.  For more info about corporate interventions and programmes open to students and academics, please contact Ansie Barnard at barnardam@ufs.ac.za.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept